骨关节炎年度回顾2023年:流行病学和治疗方法
Anthony V Perruccio1, James J Young2, Jessica M Wilfong3
1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Arthritis Community Research and Epidemiology Unit (ACREU), University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
最近的骨关节炎研究强调了疾病预测因素和结果的潜在性别差异. 有证据表明,粘性补充剂对膝关节关节炎无效,对其他注射剂需要进一步的试验.
科学领域:
- 整形外科 整形外科 整形外科
- 类风湿病学 类风湿病学
- 流行病学 流行病学
背景情况:
- 骨关节炎 (OA) 是一种常见的退行性关节疾病,具有重大公共卫生影响.
- 了解OA流行病学和治疗进展对于改善患者的治疗结果至关重要.
研究的目的:
- 审查骨关节炎 (OA) 流行病学和治疗研究的最新发现.
- 为了确定关键的发展在OA风险因素,治疗和患者分层.
主要方法:
- 从2022年4月到2023年3月,对MEDLINE和EMBASE数据库进行了全面的文献搜索.
- 研究是根据它们与OA风险因素,治疗方法和表型的相关性进行选择的,重点是人类受试者和英语出版物.
- 对33项选定的研究进行了叙事性审查,将研究结果分类为OA预测因素,特定风险因素,关节内注射和OA表型.
主要成果:
- 对208项符合条件的研究的分析揭示了OA发病率和结果的潜在性别差异.
- 体重指数的变化显著影响膝盖骨关节炎的结果,而粘性补充剂对膝盖骨关节炎没有益处.
- 其他关节内注射药物的发现是可变的,OA表型确定了临床相关的差异.
结论:
- 识别OA风险因素和了解性别在疾病发展中的作用是关键的研究优先事项.
- 需要进一步的高质量试验,以超越粘性补充剂的关节内膝盖注射剂.
- 应用OA表型化策略可能有助于开发有针对性的疾病修饰疗法.
相关概念视频
Osteoclasts in Bone Remodeling
The JAK-STAT Signaling Pathway
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation


